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ABSTRACT
Objective. To assess the long-term safety of no axillary
clearance in elderly patients with breast cancer and non-
palpable axillary nodes.
Background. Lymph node evaluation in elderly patients
with early breast cancer and clinically negative axillary
nodes is controversial. Our randomized trial with 5-year
follow-up showed no breast cancer mortality advantage for
axillary clearance compared with observation in older
patients with T1N0 disease.
Methods. We further investigated axillary treatment in a
retrospective analysis of 671 consecutive patients, aged
C70 years, with operable breast cancer and a clinically
clear axilla, treated between 1987 and 1992; 172 received
and 499 did not receive axillary dissection; 20 mg/day
tamoxifen was prescribed for at least 2 years. We used
multivariable analysis to take account of the lack of
randomization.
Results. After median follow-up of 15 years (interquartile
range 14–17 years) there was no signiﬁcant difference in
breast cancer mortality between the axillary and no axillary
clearance groups. Crude cumulative 15-year incidence of
axillary disease in the no axillary dissection group was low:
5.8% overall and 3.7% for pT1 patients.
Conclusions. Elderly patients with early breast cancer and
clinically negative nodes did not beneﬁt in terms of breast
cancer mortality from immediate axillary dissection in this
nonrandomized study. Sentinel node biopsy could also be
foregone due to the very low cumulative incidence of
axillary disease in this age group. Axillary dissection
should be restricted to the small number of patients who
later develop overt axillary disease.
In Western countries, nearly a third of breast cancers
occur in patients over 65 years of age.
1 The probability of
developing the disease increases with age, and greatest
incidence is in women aged 75–79 years.
2 The gold-stan-
dard treatment for elderly patients with breast cancer is
surgery. Randomized clinical trials that compared tamox-
ifen as sole initial treatment with surgery in elderly patients
with operable breast cancer showed no signiﬁcant differ-
ence between the arms in terms of survival, but
unacceptably high local relapse rates in the tamoxifen
group: most of these patients required surgery to control
local disease progression.
3–6 Given the central role of
surgery as primary therapy, the question arises as to whe-
ther surgical evaluation of the axilla can be safely omitted
in elderly patients with primary breast cancer and clinically
negative axillary nodes.
Axillary dissection is no longer a routine part of the
surgical treatment of breast cancer, having been replaced
by the less invasive sentinel node biopsy in women with a
clinically negative axilla.
7–10 In fact, axillary surgery is
now considered mainly a staging procedure that does not
seem to inﬂuence breast cancer mortality, since the risk of
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behavior of the primary.
11 Axillary surgery seems even less
important in elderly women because of their high mortality
from competing events and the ability of hormone therapy
to achieve long-term disease control.
12,13
Five-year results of our randomized trial comparing pri-
mary surgery with and without axillary clearance in T1N0
breast cancer patients C65 years of age showed that axillary
surgery may be safely omitted without affecting breast
cancer mortality or overall survival.
14 The outcome of this
trial fully supported the results of our previous retrospective
analysis of consecutive prospectively recruited elderly
patients with early breast cancer who also received conser-
vative surgery with or without axillary dissection: After
median follow-up of 75 months there was no difference in
breast cancer mortality between the two groups.
15 In this
paper we present 15-year follow-up results from the same
nonrandomized cohort.
PATIENTS AND METHODS
Patients and Treatment
Between January 1987 and December 1992, 1,451 con-
secutive patients aged C70 years presented at the Istituto
Nazionale Tumori, Milan, with primary breast cancer. The
present study is concerned with the 671 patients of our pre-
vious study with operable invasive breast cancer and no
palpableaxillarynodeswhounderwentconservativesurgery
with (172 patients) or without axillary dissection (499
patients).
15 Patients with synchronous bilateral breast car-
cinoma, distant metastasis at diagnosis or previous cancer at
another site were excluded, as were patients with involved
resectionmargins,sincetheywerecandidatesforre-excision
or radiotherapy.
Postoperative radiotherapy to the breast (not the axilla)
was administered to 229 patients and started within 4 weeks
of surgery. A cobalt unit or a 6-MeV linear accelerator was
usedto deliver atotal of50 Gy(daily target doseof 2 Gy)to
the residual breast parenchyma in two opposing tangential
ﬁelds over 5 weeks. A 10 Gy boost was given to the tumor
bed. Whether or not axillary dissection and radiotherapy
were given depended on patient preference and the opinion
of the treating physician. Regardless of hormone receptor
statusallpatientswereprescribed20 mg/daytamoxifenafter
surgery for at least 2 years.
Hormone Receptor Determination
Tumor specimens were assayed for estrogen receptor
(ER) and progesterone receptor (PgR) levels using the
dextran-coated charcoal technique according to Ronchi
et al.
16 Receptors levels were expressed in fmol mg
-1
cytosol protein. Tumors with ER concentration B10 fmol
cytosol protein were considered ER negative (ER-); those
with PgR concentration B25 fmol cytosol protein were
considered PgR negative (PgR-). Tumors with receptor
content above these values were considered receptor
positive (ER?,P g R ?).
Follow-Up
Patients were seen every 6 months at the outpatient
department of our institute for the ﬁrst 5 years, and yearly
thereafter. Mammography and chest X-ray were performed
annually, and bone scan every 2 years. Disease status or
cause of death was ascertained from clinical records or by
contacting patients’ general practitioners for patients no
longer in follow-up.
Median follow-up was 180 months (interquartile range
168–199 months) in the group without axillary dissection,
and 196 months (174–216 months) in the group with
axillary dissection.
Statistical Analysis
The main endpoint for investigating the prognostic
effect of axillary dissection was breast cancer death.
Additional endpoints were: axillary relapse (in patients not
receiving axillary dissection), distant metastasis, and ipsi-
lateral breast tumor recurrence (IBTR). Date of surgery
was taken as time zero for all analyses; in the absence of
any event, time was censored at the hypothetical study
closing date of June 30, 2006. Analyses were performed in
a competing-risk framework: when analyzing breast cancer
mortality, competing events were death from other malig-
nancy or from other causes; when analyzing each of the
breast cancer events (axillary relapse, distant metastasis,
IBTR), competing events were the other two possible
events, as well as contralateral cancer, other malignancy,
and death without evidence of breast disease.
17
For descriptive purposes we estimated the crude (unad-
justed) cumulative incidences of axillary relapse, distant
metastasis, and breast cancer death for different axillary
treatment and treatment-covariate subsets.
17 Cumulative
incidence curves were compared using the Gray test.
18
The main analysis, to examine the prognostic effect of
axillary dissection, was performed in a multivariable set-
ting, because the study was not randomized and treatment
effect estimation had to take into account imbalances
between the groups for baseline and prognostic character-
istics. Cox models were used to investigate effect of
treatment (axillary dissection versus no axillary dissection)
on distant metastasis and breast cancer death, by estimating
126 G. Martelli et al.treatment hazard ratios with corresponding 95% conﬁdence
intervals. The models included prognostic factors (post-
operative breast radiotherapy, pathological tumor size,
histologic type, receptor status) modeled using dummy
variables, and also propensity score as a linear term to
adjust for imbalances in baseline variables inﬂuencing the
decision to perform axillary dissection.
15,19
We also used a multivariable Fine and Gray model to
perform a statistical comparison of cumulative incidence of
breast cancer mortality in the groups that received and did
not receive axillary dissection, adjusting for baseline and
prognostic characteristics.
20 We then ran another model
that included the axillary dissection 9 pT interaction term
to test the heterogeneity of adjusted cumulative incidence
of breast cancer mortality in the groups that received
and did not receive axillary dissection, according to pT
categories.
Similar Fine and Gray models (including axillary dis-
section, covariates, radiotherapy propensity score, and in
another model, the radiotherapy 9 pT interaction) were
used for statistical comparison of cumulative IBTR inci-
dence in the groups that received and did not receive
residual breast radiotherapy, according to pT categories.
In both the Cox and Fine and Gray models the prog-
nostic factors were tested by two-sided Wald tests.
p-Values \0.05 were considered signiﬁcant. The SAS
statistical package and R software were used to carry out
the analyses.
21,22
RESULTS
Clinical characteristics by axillary treatment group for
the entire series are presented in Table 1. Age distribution
was similar in the two groups. Radiotherapy was performed
more often in the axillary dissection group (chi-square
p\0.001). Most patients had pT1 disease, with greater
frequency in the axillary dissection group (chi-square
p\0.001). Inﬁltrating ductal carcinoma was the predom-
inant histologic type; the axillary dissection group had a
higher percentage of both ductal and lobular carcinomas
(chi-square p = 0.008).
Concentrations of ER and PgR receptors were deter-
mined in 641 patients, 617 of whom (91.6%) were receptor
positive (ER?, PgR? or both), with 403 patients (62.9%)
positive for both receptors, and 54 (8.4%) negative for
ER and PgR. Receptor status differed slightly between
the axillary and no axillary treatment groups (chi-square
p = 0.054; ER-/PgR? and low-frequency ER-/PgR-
fused).
Table 2 presents the distribution of ﬁrst events and
causes of death by treatment group, together with corre-
sponding 15-year crude cumulative incidence estimates.
Table 3 shows estimates of 15-year crude cumulative
incidence of main adverse events for each group in relation
to postoperative radiotherapy and tumor variables. Note
that these estimates are not covariate adjusted, so com-
parison between treatment groups is likely to be misleading
TABLE 1 Characteristics of
671 elderly patients with
operable breast cancer and no
palpable axillary nodes who
underwent conservative surgery,
divided into axillary dissection
and no axillary dissection
groups
IQR interquartile range
a Percentages on 641 available
values
No axillary dissection
(N = 499)
Axillary dissection
(N = 172)
Overall group
(N = 671)
Age (years), median (IQR) 77 (74–81) 74 (71–77) 76 (73–80)
Postoperative RT to breast
Yes 145 (29.1%) 84 (48.9%) 229 (34.1%)
No 354 (70.9%) 88 (51.1%) 442 (65.9%)
Pathological tumor size
pT1 296 (59.3%) 134 (77.9%) 430 (64.1%)
pT2 164 (32.9%) 33 (19.2%) 197 (29.4%)
pT3 3 (0.6%) 0 (–) 3 (0.4%)
pT4b 36 (7.2%) 5 (2.9%) 41 (6.1%)
Histological type
Inﬁltrating ductal carcinoma 328 (65.7%) 120 (69.8%) 448 (66.7%)
Inﬁltrating lobular carcinoma 106 (21.2%) 44 (25.6%) 150 (22.3%)
Other inﬁltrating carcinomas 65 (13.1%) 8 (4.6%) 73 (11.0%)
Receptor status
a
ER (fmol/mg), median (IQR) 177 (63–332) 100 (24–261) 159 (55–307)
PgR (fmol/mg), median (IQR) 83 (1–363) 39 (1–175) 68 (1–316)
ER-/PgR- 35 (7.3%) 19 (11.9%) 54 (8.4%)
ER-/PgR? 4 (0.8%) 1 (0.6%) 5 (0.8%)
ER?/PgR- 128 (26.6%) 51 (32.1%) 179 (27.9%)
ER?/PgR? 315 (65.4%) 88 (55.3%) 403 (62.9%)
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in 671 elderly patients with
operable breast cancer, by
axillary treatment group
The ﬁgures in each cell are:
number of patients and 15-year
crude cumulative incidence
estimates
Events No axillary dissection
(N = 499)
Axillary dissection
(N = 172)
Overall group
(N = 671)
First event
Ipsilateral axillary disease 30, 5.8% 0, 0% 30, 4.3%
Distant metastasis 49, 9.9% 20, 11.6% 69, 10.3%
Ipsilateral breast tumor recurrence 33, 6.3% 13, 7.7% 46, 6.7%
Contralateral breast cancer 9, 1.8% 4, 2.3% 13, 1.9%
Second primary malignancy 27, 5.6% 5, 2.9% 32, 4.9%
Death for unrelated condition 251, 49.6% 82, 41.9% 333, 47.6%
Mortality
Breast cancer 71, 14.0% 23, 13.6% 94, 13.9%
Other malignancy 22, 4.3% 3, 1.8% 25, 3.6%
Unrelated condition 284, 56.4% 92, 47.8% 376, 54.2%
TABLE 3 Breakdown of main adverse breast cancer events by postoperative radiotherapy (RT), tumor size, histological type, and receptor
status for each axillary treatment group
No axillary dissection (499 patients) Axillary dissection (172 patients)
Ipsilateral axillary
disease
Distant
metastasis
Breast cancer
death
Distant metastasis Breast cancer
death
Postoperative RT to breast
Yes 14, 9.7%
(5.9–15.9%)
18, 12.4%
(8.1–19.2%)
24, 16.6%
(11.5–24.0%)
12, 14.3%
(8.4–24.2%)
15, 17.9%
(11.2–28.4%)
No 16, 4.2%
(2.6–7.0%)
31, 8.8%
(6.3–12.3%)
47, 12.9%
(9.8–17.0%)
8, 9.1%
(4.7–17.7%)
8, 9.6%
(4.9–18.9%)
Pathological tumor size
pT1 12, 3.7%
(2.1–6.7%)
20, 6.8%
(4.4–10.4%)
32, 10.7%
(7.6–14.9%)
12, 9.0%
(5.2–15.4%)
14, 10.7%
(6.5–17.6%)
pT2–4b 18, 8.9%
(5.7–13.8%)
29, 14.3%
(10.2–20.1%)
39, 18.8%
(14.1–25.1%)
8, 21.1%
(11.2–39.4%)
9, 23.7%
(13.2–42.4%)
Histological type
Inﬁltrating lobular carcinoma 4, 3.8%
(1.4–9.9%)
16, 15.2%
(9.6–23.9%)
22, 20.9%
(14.3–30.4%)
6, 13.7%
(6.4–29.3%)
7, 16.0%
(8.0–31.9%)
Inﬁltrating ductal carcinoma 26, 7.6%
(5.2–11.1%)
29, 8.9%
(6.3–12.6%)
45, 13.3%
(10.1–17.6%)
14, 11.7%
(7.1–19.1%)
16, 13.6%
(8.6–21.6%)
Other inﬁltrating carcinoma 0, 0.0% 4, 6.2%
(2.4–16.1%)
4, 6.2%
(2.4–16.1%)
0, 0.0% 0, 0.0%
Receptor status
a
ER?/PgR? 16, 4.8%
(2.9–7.8%)
27, 8.6%
(6.0–12.4%)
39, 12.3%
(9.1–16.6%)
9, 10.2%
(5.5–19.1%)
12, 14.1%
(8.3–24.1%)
ER?/PgR- 10, 7.8%
(4.3–14.2%)
14, 11.0%
(6.7–18.0%)
22, 16.6%
(11.2–24.5%)
7, 13.8%
(6.9–27.7%)
8, 15.8%
(8.3–30.1%)
ER-
a 4, 10.3%
(4.0–26.3%)
7, 17.9%
(9.1–35.5%)
9, 23.1%
(12.9–41.3%)
3, 15.0%
(5.1–43.9%)
3, 15.0%
(5.1–43.9%)
The ﬁgures in each cell are: number of patients, 15-year crude cumulative incidence estimate, and corresponding 95% conﬁdence interval
a Only one ER-/PgR? patient developed distant metastasis (14 months after surgery, death at 17 months), this category was therefore merged
with the ER-/PgR- category as ER-. Events in the 30 patients with missing receptor status were: distant metastasis: 1 in axillary dissection
group, 1 in no axillary dissection group; breast cancer death: 1 in axillary dissection group, 0 in no axillary dissection group
128 G. Martelli et al.due to the imbalances in baseline and prognostic character-
istics.
Of the 172 patients who received axillary dissection, 58
(33.7%) had pathologically involved axillary nodes,
including 39 (29.1%) among the 134 patients with pT1
disease. Of the 499 patients who did not receive axillary
dissection, 30 developed ipsilateral axillary disease (12 in
the pT1 group): most were rescued by delayed axillary
dissection. Fifteen of these 30 patients subsequently
developed distant relapse and died of breast disease, while
11/30 died of causes unrelated to breast cancer. Median
time from primary surgery to axillary occurrence was
33 months (interquartile range 19–61 months); most (90%)
developed axillary disease in the 6 years after surgery.
The 15-year crude cumulative incidence of axillary
occurrence in the no axillary dissection group was 5.8%
[95% conﬁdence interval (CI): 4.1–8.3%], being 3.7% (CI:
2.1–6.7%) in pT1 patients.
The 15-year crude cumulative incidence of breast cancer
death was 14.0% (CI: 11.2–17.4%) in the no axillary dis-
section group and 13.6% (CI: 9.2–19.9%) in the axillary
dissection group (p = 0.657). The corresponding ﬁgures
were 10.7% (CI: 7.6–14.9%) and 10.7% (CI: 6.5–17.6%),
respectively, for pT1 patients (p = 0.836), and 18.8% (CI:
14.1–25.1%) and 23.7% (CI: 13.2–42.4%), respectively,
for pT2–4 patients (p = 0.708) (Fig. 1). Note that the
estimates in Fig. 1, like those in Tables 2 and 3, are not
adjusted for imbalances in baseline or prognostic charac-
teristics, so comparison between treatment groups is likely
to be misleading. According to the Fine and Gray model,
breast cancer death did not differ signiﬁcantly between the
two treatment groups (p = 0.480), and the effect of axil-
lary dissection on breast cancer mortality did not differ
signiﬁcantly in pT1 versus pT2–4b patients (p = 0.960 for
interaction of axillary dissection with pT) (data not shown).
Table 4 shows the results of the multivariable Cox
models for investigating the prognostic effect of treatment
on distant metastasis and breast cancer mortality with
covariate adjustment. No signiﬁcant axillary treatment
effect was observed on the two investigated end points. As
regards covariates, breast radiotherapy was not signiﬁcantly
associated with prognosis, whereas pT and histologic type
were signiﬁcantly associated with distant metastasis and
breast cancer death, with higher risks associated with[pT1
disease and lobular carcinoma. In addition, ER-negative
disease was stronglyassociated with distant metastasis, with
a hazard ratio (HR) over twice that for ER-positive/PgR-
positive disease.
Of the 229 patients given radiotherapy, 8 experienced
IBTR: 1 subsequently developed distant metastasis and
died of breast disease, and 5 died of causes unrelated to
breast cancer. Of the 442 patients not given radiotherapy,
38 had IBTR: 6 subsequently developed distant metastasis
and died of breast disease, 3 died of other malignancy, and
15 of causes unrelated to cancer. Considering the 430 pT1
patients, 7/88 (8.0%) of those given tamoxifen plus
radiotherapy developed IBTR, and 28/342 (8.2%) of those
given tamoxifen only developed IBTR. All IBTRs were
managed by conservative surgery, which was followed by
radiotherapy in eight patients in the no radiotherapy group.
The 15-year crude cumulative incidence IBTR was 3.5%
(CI: 1.8–6.9%) in patients given radiotherapy, and 8.4%
(CI: 6.1–11.5%) in those not given radiotherapy (p =
0.010). The corresponding ﬁgures for pT1 patients were
8.0% (CI: 3.9–16.3%) and 7.9% (CI: 5.4–11.5%), respec-
tively (p = 0.845); in pT2–4 patients, crude cumulative
incidences (CCIs) were 0.7% (CI: 0.1–5.2%) and 10.0%
(CI: 5.6–18.2%), respectively (p\0.001) (Fig. 2). The
Fine and Gray multivariable analysis also showed that
IBTR incidence differed signiﬁcantly between the groups
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FIG. 1 Crude cumulative incidence curves of breast cancer death for patients given and not given axillary dissection. pT1 (left); pT2–4b (right)
Elderly Patients with Breast Cancer 129given and not given radiotherapy (p = 0.041) and that the
effect of radiotherapy on IBTR differed signiﬁcantly
between the pT1 and pT2–4b groups (p = 0.014 for axil-
lary dissection 9 pT interaction) (data not shown).
DISCUSSION
The most important ﬁnding of this study is that, after
15 years of follow-up in elderly patients with clinically
node-negative early breast cancer treated by conservative
surgery and tamoxifen, there was no signiﬁcant advantage
to axillary dissection in terms of breast cancer mortality.
Among the 172 patients who received prophylactic
axillary dissection, 33.7% had positive axillary nodes on
pathologic examination (29% of patients with pT1 disease),
yet only 30/499 patients without axillary dissection (crude
15-year cumulative incidence 5.8%) including 12/296 pT1
patients (crude 15-year cumulative incidence 3.7%)
developed overt axillary disease after 15 years of follow-
up. This ﬁnding is consistent with the experience of others
that the axillary recurrence rate is much lower than the rate
of axillary involvement on pathological examination of
resected axillary nodes.
23–25 Consider, for example, the
milestone NSABP B-04 trial which compared radical
TABLE 4 Multivariable Cox analyses of inﬂuence of axillary treatment, postoperative radiotherapy (RT), tumor size, histology, and receptor
status on distant metastasis and breast cancer death
Distant metastasis Breast cancer death
HR 95%CI p-Value HR 95%CI p-Value
Axillary dissection 0.831 0.372
Yes versus no 0.9 (0.5–1.7) 0.8 (0.5–1.3)
Postoperative RT to breast 0.382 0.376
Yes versus No 0.7 (0.4–1.5) 0.8 (0.4–1.4)
Pathological tumor size 0.001 \0.001
pT2–pT4b versus pT1 3.2 (1.6–6.5) 2.8 (1.5–5.0)
Histologic type 0.022 0.011
Lobular versus all other histotypes 3.1 (1.1–9.0) 4.0 (1.4–11.4)
Ductal versus all other histotypes 1.6 (0.6–4.5) 2.4 (0.9–6.6)
Receptor status 0.107 0.251
ER?/PgR- versus ER?/PgR? 1.2 (0.7–2.2) 1.3 (0.8–2.1)
ER-
a versus ER?/PgR? 2.2 (1.1–4.4) 1.6 (0.9–3.0)
HR hazard ratio: risk increase (if[1) or decrease (if\1) associated with category versus reference category (assumed to have HR = 1). CI 95%
HR conﬁdence interval. p-Values from two-sided Wald test
a Due to low number of events the category ER-/PgR? was merged with ER-/PgR-
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FIG. 2 Crude cumulative incidence curves of ipsilateral breast tumor recurrence (IBTR) for patients given and not given radiotherapy. pT1
(left); pT2–4b (right)
130 G. Martelli et al.mastectomy with ‘‘simple’’ mastectomy in which muscles
and axillary lymph nodes (unless axillary disease became
evident during follow-up) were left in place.
23 In this study
[70% of women were aged 50 years or above. After
25 years, no signiﬁcant difference in disease-free, distant
relapse-free or overall survival was observed between
radical and simple mastectomy arms. Furthermore, only
18% subsequently developed overt ipsilateral axillary dis-
ease in the simple mastectomy arm, compared with the
40% expected based on the proportion with a positive
axilla after prophylactic axillary dissection.
The more recent Veronesi trial on patients aged over
45 years with breast cancer up to 1.2 cm had similar
ﬁndings.
24 These patients received breast-conserving sur-
gery without axillary dissection, and were randomized to
axillary radiotherapy or no axillary treatment. Distant
metastasis-free and overall survival did not differ between
the two arms, and the rate of axillary relapse in the no
axillary treatment arm was only 1.5% after 5 years.
Another recently published randomized trial on women
C60 years of age with breast cancer and a clinically node-
negative axilla compared surgery with axillary dissection
and surgery without axillary dissection followed by
tamoxifen for 5 years.
25 This study found that presence of
axillary lymph node involvement did not affect disease-
free or overall survival after median follow-up of 6.6 years.
Our own randomized trial, published in 2005 on patients
C65 years of age with T1N0 breast cancer randomly
assigned to breast-conserving surgery with or without
axillary dissection followed by tamoxifen for 5 years, also
showed no advantage in terms of breast cancer mortality or
overall survival for axillary dissection after 5 years of
follow-up.
14 Only 1.2% of patients in the no axillary dis-
section arm developed overt axillary involvement.
Two major points emerge from all these studies: rates
of overt axillary metastases in those receiving no axillary
treatment are much lower than expected; and overall
survival and breast cancer mortality do not differ between
the axillary treatment and no axillary treatment arms.
Axillary dissection may be associated with more accurate
staging and improved regional control, but it does not
affect breast cancer mortality or overall survival—most
conspicuously in older women—supporting the hypothesis
that the biologic behavior of the primary mainly deter-
mines whether metastatic spread occurs and hence
whether the patient will die of her disease.
26 The recent
hypothesis that only cancer stem cells give rise to
metastases may be of relevance here: these cells are
supposed to be slow growing and form only a small
proportion of the total population of cancer cells; they
may require many years to develop into overt disease
recurrence.
27,28 Little is known, however, regarding the
characteristics of breast cancer stem cells.
In the present study over 90% of tumors were ER?,a si s
normally the case in elderly women. Long-term tamoxifen
treatmentisknowntokeepcanceratbayformanyyear,ifnot
indeﬁnitely,andthismayhavebeenanimportantreasonwhy
the rate of overt axillary disease was low in our series.
29,30
As expected, the multivariable Cox analysis found that
large tumor size was a major predictor of distant metastases
and breast cancer death in our series, with HRs of 2.6 and
2.3, respectively, for [pT1 compared with pT1 tumors
(Table 4). Somewhat unexpectedly the Cox analysis also
showed that invasive lobular histology was a very strong
predictor of distant metastasis and breast cancer death
comparedwith other histologies (Table 4). Thisﬁnding isin
contrast to a 2004 study which found identical overall and
disease-free survival in lobular and ductal carcinoma.
31 We
also found that ipsilateral axillary disease was much more
frequent in patients with ductal histotype (Table 3). Fur-
thermore ER-negative tumors were strongly associated with
development of distant metastasis. It also appears from
Table 3 that, for both groups, postoperative radiotherapy
was associated with greater 15-year crude cumulative inci-
dence of adverse events (even though conﬁdence intervals
were wide and overlapping). This is because the groups
werenotstratiﬁed(inthistable)fortumorsize.Largertumor
size in this nonrandomized study will have increased the
likelihood of both adverse events and also increased the
likelihood of receiving radiotherapy. The multivariable
analysis(Table 4)showedradiotherapy tohave no inﬂuence
on outcome in the two groups. However, while 15-year
crude cumulative incidence of IBTR in elderly patients with
pT1 breast cancer did not differ signiﬁcantly between the
radiotherapyandnoradiotherapygroups (andwasfairlylow
at about 8%), the incidence of IBTR was much higher
(p\0.001, Fig. 2) in patients with larger cancers who did
not receive radiotherapy. The role of radiotherapy in con-
servativelytreatedpatientsagedC70 yearswithT1N0ER?
breast cancer was investigated in a recent trial.
32 The
patients were randomly assigned to postoperative radio-
therapy versus no postoperative radiotherapy to the breast,
followed byadjuvanttamoxifen.After5 years,ratesoflocal
relapse were 1% in the radiotherapy group and 4% in the no
radiotherapy group, with no difference in overall survival or
breast cancer mortality. In the Veronesi trial that investi-
gated the importance of breast radiotherapy in patients with
breast cancer up to 2.5 cm receiving conservative surgery,
the difference in local relapse rate between the radiotherapy
and no radiotherapy arms decreased with advancing age, so
that in women aged C55 years the difference was minimal,
and in women aged C65 years the difference was no longer
present.
33
These data suggest that, in elderly patients with early
breast cancer receiving adequate conservative surgery and
long-term tamoxifen, radiotherapy may be safely omitted.
Elderly Patients with Breast Cancer 131Nevertheless our data strongly suggest that radiotherapy is
essential in older patients with large tumors.
To conclude, data from the present nonrandomized
study and several other studies including randomized trials
strongly suggest that elderly patients with early breast
cancer and clinically negative axillary nodes do not beneﬁt
from axillary dissection.
14,23–25 Sentinel node biopsy
should also be omitted, as axillary dissection did not
impact breast cancer mortality in our study, and the path-
ological information provided by resected axillary nodes is
unlikely to inﬂuence adjuvant therapy options, particularly
since hormonal therapy is standard for all patients with
receptor-positive disease.
We also found that elderly patients with receptor-neg-
ative disease had signiﬁcantly greater rates of distant
metastases and breast cancer death than those with recep-
tor-positive tumors, and these patients present a treatment
dilemma since hormonal therapy is not indicated. Thus
treatment for early-stage breast cancer in elderly patients
should be reevaluated; in particular, axillary node dissec-
tion should be restricted to patients with clinically involved
nodes. We note, ﬁnally, that it would be preferable to
conﬁrm our ﬁndings with a randomized trial, notwith-
standing the difﬁculties in conducting randomized trials in
elderly patients, since undetected differences between the
groups could have inﬂuenced the result.
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